A drug evaluation is a systematic process used to determine whether a substance is safe, effective, and suitable for its intended purpose. The term has two distinct meanings depending on context: in medicine and pharmaceutical regulation, it refers to the multi-year process of testing and approving new medications before they reach the public. In law enforcement, it refers to a standardized 12-step examination used to determine whether a person is impaired by drugs. Both are structured, evidence-based procedures with clear protocols.
Drug Evaluation in the Pharmaceutical Sense
When a pharmaceutical company develops a new medication, that drug must undergo rigorous evaluation before it can be sold to the public. In the United States, this process is overseen by the FDA’s Center for Drug Evaluation and Research (CDER), which assembles a review team of medical officers, statisticians, pharmacologists, toxicology specialists, chemists, and microbiologists. Each team member evaluates the drug from their area of expertise, but they’re all working to answer the same core questions: Is this drug safe? Does it actually work for its intended use? Do the benefits outweigh the risks? And is it being manufactured consistently and correctly?
Similar evaluation systems exist worldwide. In England, the National Institute for Health and Care Excellence (NICE) weighs clinical benefit against cost. In the Netherlands, evaluators assess necessity, effectiveness, cost-effectiveness, and feasibility. Sweden uses a framework based on human dignity, need, and cost efficiency. The specifics vary by country, but every system requires proof that a drug works and that its risks are acceptable.
How New Drugs Move Through Clinical Trials
Before reaching the FDA review team, a drug must first survive a series of clinical trials, each larger and more demanding than the last. According to the National Institutes of Health, these trials unfold in four phases.
Phase I tests the drug in a small group of 20 to 80 people for the first time. The goal is basic safety: researchers want to identify side effects and understand how the body processes the drug. Phase I isn’t about whether the drug works yet.
Phase II expands to 100 to 300 participants. Now researchers begin measuring whether the drug is effective while continuing to monitor safety. Many drugs fail here because they simply don’t perform well enough in real patients.
Phase III involves 1,000 to 3,000 people. This is the stage that confirms effectiveness, compares the drug to existing treatments, and gathers enough safety data to support a labeling decision. Phase III trials are the most expensive and time-consuming part of the process.
Phase IV happens after approval. Once a drug is on the market and being used by a much larger population, researchers continue tracking its safety and looking for rare side effects that smaller trials couldn’t detect.
The overall success rate is sobering. Roughly 90% of drugs that enter Phase I clinical trials never make it to approval. That figure doesn’t even include the many candidates eliminated during preclinical (animal) testing, which would push the failure rate even higher. Drugs fail for many reasons, but the most common are inadequate effectiveness and unacceptable safety profiles.
What Evaluators Actually Look At
The FDA review team examines a drug from several angles simultaneously. Medical officers analyze every clinical study submitted, evaluating study design, the quality of the investigators who ran the trials, and the strength of the efficacy data. Pharmacology and toxicology specialists review animal studies to assess the drug’s potential for toxic effects, including reproductive and fetal harm. Statisticians independently analyze the trial data to verify whether the reported results hold up.
Behind the scenes, chemists and microbiologists evaluate the drug’s physical composition, manufacturing process, stability over time, and purity. Pharmaceutical-grade materials must meet strict purity standards, with impurities quantified down to the 0.1% level. Reviewers also assess how the body absorbs, distributes, metabolizes, and eliminates the drug, which determines proper dosing and helps predict drug interactions.
Evaluation Doesn’t Stop After Approval
Pre-approval studies typically involve only several hundred to several thousand patients, which means rare side effects can go undetected. That’s why the FDA maintains an active post-market surveillance system. The FDA Adverse Event Reporting System (FAERS) is a database that collects safety reports on every approved drug and biologic product. A team of safety evaluators and epidemiologists reviews these reports to detect new safety signals.
The MedWatch program allows both healthcare professionals and the general public to voluntarily report serious reactions. Manufacturers are also required by law to submit adverse event reports and to flag any deviations from good manufacturing practices. Based on this ongoing monitoring, the FDA can update a drug’s labeling, issue safety communications to healthcare providers, or in rare cases reconsider whether a drug should remain on the market. The agency also conducts unannounced inspections of drug production facilities to verify that manufacturers are following the terms of their approval.
How Countries Weigh Cost and Value
Safety and efficacy are universal requirements, but many countries add another layer: economic evaluation. Most health technology assessment systems use some form of cost-per-outcome analysis to decide whether a new drug represents good value for money. In England and Sweden, the preferred measure is cost per quality-adjusted life year (QALY), which captures both how much longer a treatment helps someone live and how much it improves their quality of life during that time.
France takes a different approach, rating each drug’s “medical benefit” and “improvement of medical benefit” compared to existing options, then using those ratings to set reimbursement and pricing. Poland requires a clinical effectiveness analysis, an economic analysis, and a healthcare system impact analysis before considering a drug complete for review. These economic evaluations exist because approving a drug as safe and effective is a separate question from deciding whether a healthcare system should pay for it.
Drug Evaluation in Law Enforcement
In a completely different context, a “drug evaluation” refers to a structured examination conducted by a Drug Recognition Expert (DRE), a specially trained law enforcement officer. This evaluation is used when someone is suspected of driving under the influence of drugs and a breath alcohol test doesn’t explain the observed impairment. If a driver’s alcohol concentration is above 0.08, a DRE evaluation typically isn’t conducted because alcohol already accounts for the impairment.
The evaluation follows a standardized 12-step protocol:
- Breath alcohol test to establish a baseline and rule out alcohol as the sole cause of impairment
- Interview of the arresting officer to learn about the suspect’s driving behavior and roadside conduct
- Preliminary examination including questions and initial eye tests to screen for medical conditions that might explain the symptoms
- Eye examinations testing for horizontal gaze nystagmus, vertical gaze nystagmus, and lack of convergence (involuntary eye movements that different drug categories produce)
- Divided attention tests including the Romberg Balance, Walk and Turn, One Leg Stand, and Modified Finger to Nose
- Vital signs including three separate pulse readings, blood pressure, and body temperature
- Dark room examinations measuring pupil size under three lighting conditions using a pupilometer and penlight
- Muscle tone examination
Additional steps include checking for injection sites, interviewing the suspect, forming an opinion about which drug category is responsible for the impairment, and requesting a toxicology sample (typically blood or urine) to confirm the evaluation. The entire process is designed to systematically narrow down which of seven major drug categories might be affecting the person, based on the specific combination of physical signs observed.
Whether in a pharmaceutical lab or on the side of a road, a drug evaluation follows a defined protocol designed to produce reliable, evidence-based conclusions about how a substance is affecting the human body.